核心观点公司2025年前三季度业绩稳步提升。2025年前三季度公司实现营收91.16亿元(+0.4%)，归母净利润17.54亿元(+4.9%)，扣非归母净利润17.12亿元(+5.0%)。2025年三季度营收28.44亿元(+1.6%)，归母净利润4.73亿元(-5.7%)，扣非归母净利润4.54亿元(-4.6%)。公司核心产品进展顺利，创新品种即将商业化。制剂板块中消化、精神、中药等领域大品种的...
Source Link核心观点公司2025年前三季度业绩稳步提升。2025年前三季度公司实现营收91.16亿元(+0.4%)，归母净利润17.54亿元(+4.9%)，扣非归母净利润17.12亿元(+5.0%)。2025年三季度营收28.44亿元(+1.6%)，归母净利润4.73亿元(-5.7%)，扣非归母净利润4.54亿元(-4.6%)。公司核心产品进展顺利，创新品种即将商业化。制剂板块中消化、精神、中药等领域大品种的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.